Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 19 NOVEMBER 2024

Corporate Transparency Act Reporting Is A Reality

Thompson Coburn LLP
Explore more from Thompson Coburn LLP

If you have not already done so, now is the time to investigate whether your company may be subject to the filing requirements of the Corporate Transparency Act (CTA).

United StatesCorporate/Commercial Law
Matthew Hafter
Matthew Hafter
Eileen Duffy Robinett
Eileen Duffy Robinett
Barry Fischer
Barry Fischer
Author LinkedIn connections

If you have not already done so, now is the time to investigate whether your company may be subject to the filing requirements of the Corporate Transparency Act (CTA). If your company is a corporation, limited liability company, limited partnership or other entity created by a filing with a State's Secretary of State or similar governmental authority, your company will be required to file under the CTA unless it comes within one of the 23 CTA exemptions.

FinCEN has published a Small Entity Compliance GuideandFrequently Asked Questions to assist companies in understanding the CTA, its exemptions, and the filing requirements. Thompson Coburn LLP has many useful resources on our Corporate Transparency Act (CTA) Resources page and can assist in answering questions you may have about how the CTA may apply to your company.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Healthcare Trends & Transactions Q2 2026

Healthcare M&A activity maintained steady momentum through Q2 2026, driven by physician practice consolidation, AI-enabled technology acquisitions, and strategic outpatient expansion. Private equity investment persisted despite intensifying regulatory scrutiny of MSO arrangements, while digital health buyers paid significant premiums for platforms demonstrating production-grade AI capabilities and proprietary data assets.
United StatesCorporate/Commercial Law
Bass, Berry & Sims PLC
Bass, Berry & Sims PLC
Article

CLIENT ALERT: 2026 Mid-Year Update On SEC And CFTC Enforcement

The SEC and CFTC have fundamentally shifted their enforcement approach in 2026, moving away from high-volume technical violations toward targeted actions addressing serious fraud and market manipulation. This mid-year update examines new leadership priorities, enhanced inter-agency coordination, revised cooperation policies, the elimination of "no-deny" settlement provisions, and a landmark Supreme Court ruling on disgorgement that collectively reshape the regulatory landscape for market participants.
United StatesCorporate/Commercial Law
Sher Tremonte
Sher Tremonte
Article

Sanofi And Regeneron Expand Immunology Collaboration In Deal Worth Up To $8 Billion

Sanofi and Regeneron Pharmaceuticals announce a major expansion of their immunology partnership, committing up to $8 billion to develop and commercialize four long-acting antibodies targeting key inflammatory pathways. The collaboration includes a $1 billion upfront payment and milestone-based payments, with both companies sharing development costs and future profits equally.
United StatesCorporate/Commercial Law
Goodwin Procter LLP
Goodwin Procter LLP